Press releases

* (R) = Regulatory press releases

May 21, 2024

(R) Cantargia publishes interim report for the first quarter of 2024
May 16, 2024

(R) Third party withdraws appeal related to Cantargia patent
May 7, 2024

Invitation to presentation of Cantargia’s interim report for Q1 2024 on May 21 at 3.00 p.m. CEST
Apr 18, 2024

(R) Cantargia publishes Annual Report for 2023
Apr 18, 2024

(R) Notice of annual general meeting in Cantargia AB (publ)
Apr 17, 2024

Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition
Apr 10, 2024

Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal
Apr 8, 2024

Cantargia presents unique effects of nadunolimab in pancreatic cancer
Apr 2, 2024

Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis
Mar 27, 2024

Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB